Liquid Brain® for Antibody Discovery
Gain unprecedented insight into biophysical behaviour and transform your developability process today.
Make rigorous developability calls earlier than ever before
Capture continuous, real-time molecular responses and generates high-dimensional fingerprints of any material.
Reveal how potential antibodies behave in real-world conditions and under stress.
Make developability calls as early as hit-ID across fragments, bispecifics, ADCs, nanobodies, and more.
Unlock a whole new class of thermodynamic data for antibody development
Trastuzumab
Sirukumab
A molecular VIBE check
Using Liquid Brain enabled VIBE (Variations in Interfacial Behavior and their Evolution), we generate time series data about molecular behaviour under stress.
Even by glancing at a time series over a few ms (graphics on the left), you can see the difference between a stable (green) and unstable (red) molecule in a particular test.
Learn more through this preprint.
The first panoramic assay
Out of 12 leading assays, The Liquid Brain®’s VIBE1 is the only assay that shows collective connectivity to all the properties being tested.
This view only covers one of the many dimensions VIBE1 can measure, with each dimension corresponding to a different subset of properties.
Spearman rank correlation heatmap comparing VIBE1 to 12 conventional biophysical assays from Jain et al. across 135 monoclonal antibodies.
VIBE1 scores are plotted by the highest clinical stage reached for each of the 236 mAbs analysed
An early-stage filter
The fraction of high-scoring antibodies declines across clinical stages: 20.69% in Phase I, 21.74% in Phase II, 14.29% in Phase III, and just 6.15% among approved drugs.
Notably, 80% of antibodies still active in trials exhibit low VIBE1 scores—supporting the descriptor’s potential utility as an early, conservative filter.
Maximum insight with minimal input
10µg
Get maximum insight with minimal input and identify liabilities in minutes with just 10µg of material.
1000x
Screen 1000× more candidates for developability risks than traditional tools allow.
200+
Clinically benchmarked on 200+ clinical-stage antibodies, identifying failures missed by conventional assays.
How early access works
Ship your sample
Our systems are designed to work with all antibody materials and can generate rapid insights from just 10µg of sample in a 96-well plate format.
The Liquid Brain is label-free, buffer & solvent agnostic, with no immobilisation required. Every sample is processed in a fully automated, time-stamped, thermal environment.
We capture your sample’s dynamic molecular fingerprint
Our programmable workflows excite the sample, capturing what happens when a molecule is under stress, producing high-bandwidth, multimodal sensory readout.
From this, we regenerate the unique thermodynamic state diagram of the molecule(s) in question, revealing continuous biophysical behaviours, not just binary risk calls.
Explore your antibody’s raw thermodynamic data
Our fully automated data pipeline generates high-dimensional, interpretable insight in just 20 min per sample. This allows you to correlate classifications with several other multi-parameter assay but also flag failures missed by conventional tools.
Our high-dimensional thermodynamic data is generated in real-time, traceable, recallable and accessible via API. All your data is stored privately and accessible via our interactive UI & collaborative platform.
Join our Insight Platform (Limited Access)
Gain access to a unified environment where you can combine Liquid Brain® fingerprints with your own assay data or state-of-the-art in silico predictors. Use it to triage candidates more effectively or investigate molecule-specific liabilities with greater precision.
Whether you're integrating multimodal data to guide early decisions or diagnosing risks to take corrective action, our platform gives you the tools to act confidently.
Are you developing predictive models? Reach out to test and share them on our platform.
The Liquid Brain® is already helping R&D leaders across the world
The Liquid Brain® is already helping R&D leaders across the world
Dr Nimish Gera, Scientific Co-Founder, VP
Developability is a key aspect of our early-stage antibody discovery and engineering process. We chose Liquid Brain because conventional assays just don’t provide the dynamic range or resolution at that stage. They’re hard to run, and they often miss the nuances that matter. Liquid Brain fundamentally unlocks generating this data early in process from as little as 10 micrograms of material.
We’ve now worked with Apoha across multiple pilot programs, including a recent 70-antibody case study on a novel modality. In one early study, Liquid Brain correctly flagged liabilities between antibodies that differed by just 1–2 amino acids! Based on these results, we’re now integrating Liquid Brain at the very start of our next program to get developability insights right at hit identification.
What if a machine could help you feel the true texture of a material, the taste of an ingredient, the efficacy of a new drug?